Table 4.
Patient 1 | Patient 2 | Patient 3 | |||||||
---|---|---|---|---|---|---|---|---|---|
Before | After OLT | 9-months | Before | After BVZ | 9-months | Before | After BVZ | 9-months | |
Hemoglobin (g/L) | 127.3 | 104.7 | 101.5 | 72.5 | 114.4 | 104.7 | 98.3 | 161.4 | 136.9 |
ALAT (U/L) | 18 | 121 | 44 | 18 | 23 | 21 | 44 | 38 | 45 |
ALP (U/L) | 89 | 215 | 232 | 112 | 117 | 100 | 125 | 85 | 100 |
Bilirubin (mg/dL) | 0.58 | 1.05 | 0.7 | 0.88 | – | – | 1.4 | 1.58 | 25 |
INR | 1.2 | 1.0 | – | 1.4 | – | – | 1.1 | 1.5 | 1.2 |
Bevacizumab side effects | No bevacizumab | Vulnerable and flossy nails | Dry, itchy skin, alopecia |
OLT orthotopic liver transplantation, BVZ bevacizumab, ALAT alanine aminotransferase, ALP alkaline phosphatase, INR international normalized ratio